FEEDBACK FROM 1,330 PATIENT GROUPS WORLDWIDE PUBLISHED APRIL 2018

THE CORPORATE REPUTATION OF PHARMA IN 2017 THE PATIENT PERSPECTIVE — GLOBAL EDITION

CONTENTS

1 EXECUTIVE SUMMARY

9 METHODOLOGY

14 PATIENT-GROUP RELATIONSHIPS WITH PHARMA, 2017

18 INDUSTRY-WIDE FINDINGS, 2017 22 RANKINGS OF THE 46 PHARMA COMPANIES, 2017 v. 2016 AMONG PATIENT GROUPS FAMILIAR WITH THE COMPANIES

37 POSITIONING OF THE 46 PHARMA COMPANIES, 2017 v. 2016 AMONG PATIENT GROUPS THAT WORK/PARTNER WITH THE COMPANIES

52 PROFILES OF THE 46 COMPANIES, 2017

APPENDICES

I. WHAT 9 PHARMACEUTICAL COMPANIES SAY ABOUT THEIR

PATIENT-ORIENTED ACTIVITIES, 2017-2018

II. PROFILES OF RESPONDENT PATIENT GROUPS, 2017

TABLES AND CHARTS

2 THE PHARMA INDUSTRY’S CORPORATE REPUTATION, 2011-2017 (ACCORDING TO PATIENT GROUPS)

3 PHARMA-INDUSTRY REPUTATION AT BEING INNOVATIVE, 2011-2017 (ACCORDING TO PATIENT GROUPS)

5 COMPANIES SHOWING THE BIGGEST IMPROVEMENT IN OVERALL RANKINGS FOR CORPORATE

REPUTATION, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS FAMILIAR WITH THE COMPANY)

5 COMPANIES SHOWING THE BIGGEST IMPROVEMENT IN OVERALL POSITIONINGS FOR CORPORATE

REPUTATION, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS THAT WORK/PARTNER WITH THE

COMPANY)

6 COMPANY NET PROMOTER SCORE, 2017—COMPARED WITH COMPANY POSITION IN THE LEAGUE TABLE

(ACCORDING TO PATIENT GROUPS THAT WORK WITH/PARTNER WITH THE COMPANY)

7 COMPANY AVERAGE NET PROMOTER SCORE, 2017—PLOTTED AGAINST COMPANY POSITION IN THE

PATIENT-GROUP-PARTNER LEAGUE TABLE

11 PERCENTAGE OF PATIENT GROUPS WORKING WITH EACH COMPANY, 2017—AS A PROPORTION OF

PATIENT GROUPS FAMILIAR WITH THE COMPANY

12 THE 12 INDICATORS OF CORPORATE REPUTATION USED IN THE 2017 PATIENT-GROUP SURVEY

13 PERCENTAGE OF PATIENT GROUPS STATING THAT “NONE” OF THE 46 COMPANIES WERE “BEST” FOR

EACH INDICATOR (INDICATOR BY INDICATOR)

15 LEVELS OF FAMILIARITY OF PATIENT GROUPS WITH 46 COMPANIES, 2017 (AND LEVELS OF PATIENT-

GROUP PARTNERSHIPS WITH THE PHARMA COMPANIES)

16 LEVELS OF FAMILIARITY OF PATIENT GROUPS WITH 46 COMPANIES, 2017—RANKED HIGH TO LOW

16 PHARMA COMPANIES AND LEVELS OF PATIENT-GROUP PARTNERSHIPS, 2017—RANKED HIGH TO LOW

17 TYPES OF RELATIONSHIPS THAT PATIENT GROUPS HAVE WITH PHARMACEUTICAL COMPANIES, 2017

19 THE CORPORATE REPUTATION OF THE PHARMACEUTICAL INDUSTRY, 2017 v. 2016—COMPARED WITH

EIGHT OTHER HEALTHCARE SECTORS

19 THE CORPORATE REPUTATION OF THE PHARMACEUTICAL INDUSTRY, 2011-2017

20 PERCEPTIONS OF THE EFFICACY OF THE PHARMACEUTICAL INDUSTRY AT VARIOUS ACTIVITIES OF IMPORTANCE TO PATIENT GROUPS, 2017 [CHART AND TABLE]

21 PERCEPTIONS OF THE EFFICACY OF THE PHARMACEUTICAL INDUSTRIES AT VARIOUS ACTIVITIES IMPORTANT TO PATIENT GROUPS, 2011-2017

22 RANKINGS OF INDIVIDUAL PHARMA COMPANIES, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS FAMILIAR WITH THE COMPANY)

37 POSITIONINGS OF INDIVIDUAL PHARMA COMPANIES, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS THAT WORK/PARTNER WITH THE COMPANY)

TABLES AND CHARTS, continued

52 PROFILES OF THE 46 COMPANIES, 2017

CHARTS AND TABLES FOR EACH OF THE 46 COMPANIES:

Number of patient groups claiming familiarity with the company, 2017.

Number of patient groups saying that they had a working relationship with the company, 2017.

Company scores among patient groups familiar with the company, and which worked with the company, for each of the 12 indicators of corporate reputation, 2017.

Percentage of the patient groups that worked with the company, but which also worked with other companies, 2017.

Profile of respondent patient groups familiar, and working, with the company, 2017: country headquarters; specialties; geographic remit; and types of relationships.

Snapshot view: where the company sits in the corporate rankings for each of the 12 indicators (in the higher, the middle, or the lower tier), 2017.

Overall rankings for the company according to patient groups familiar with the company, 2017.

Overall positionings for the company according to patient groups that work with the company, 2017.

Company rankings for each of the 12 indicators according to patient groups familiar, or working, with the company, 2017 v. 2016.

The company’s average scores across all indicators of corporate reputation, 2011-2017.

The company’s net promoter score, 2017.

TABLES AND CHARTS, continued

Page COMPANY PROFILE

54 ABBVIE

56 ACORDA THERAPEUTICS

58 ALLERGAN

60 ALMIRALL

62 AMGEN

64 ASTELLAS PHARMA

66 ASTRAZENECA

68 BAYER

70 BIAL

72 BIOGEN

74 BOEHRINGER INGELHEIM

76 BRISTOL-MYERS SQUIBB

78 CELGENE

80 CHIESI FARMACEUTICI

82 CSL BEHRING

84 DAIICHI SANKYO

86 EISAI

88 ELI LILLY (LILLY)

90 FERRING

92 GEDEON RICHTER

94 GILEAD SCIENCES

96 GRIFOLS

98 GRÜNENTHAL

100 GSK

102 IPSEN

104 JANSSEN

106 LEO PHARMA

108 LUNDBECK

110 MENARINI

112 MERCK & CO

114 MERCK KGaA

116 NOVARTIS

118 NOVO NORDISK

120 OCTAPHARMA

122 OTSUKA

124 PFIZER

126 PIERRE FABRE LABORATORIES

128 ROCHE

130 SANOFI

132 SERVIER

134 SHIRE

136 TAKEDA

138 TEVA

140 UCB

142 VERTEX PHARMACEUTICALS

144 ViiV HEALTHCARE

CONTACT DETAILS: PATIENTVIEW LTD REGISTERED OFFICE: ONE FLEET PLACE, LONDON, EC4M 7WS, UK TEL: +44-(0)1547-520-965 EMAIL: REPORT@PATIENT-VIEW.COM REGISTERED IN ENGLAND, NUMBER: 3944382 DATA PROTECTION REGISTRATION NUMBER: Z7133076 VAT REGISTRATION NUMBER: GB-760-985-885

COPYRIGHT © 2018 PATIENTVIEW LTD ALL RIGHTS RESERVED THIS BOOKLET IS THE PROPERTY OF PATIENTVIEW, AND NO PART MAY BE REPRODUCED WITHOUT PERMISSION, OR PASSED ON TO ANY THIRD PARTY WITHOUT THE PERMISSION OF PATIENTVIEW